4 Chinese Stocks that rocked 2017.

Tencent Holdings

YTD gain: 111.5 per cent
The Shenzhen-based internet firm, which ranks as the world’s largest video game company by revenue, has continued its phenomenal run in the Hong Kong stock market amid a series of strategic acquisitions as well as the spin-off of its e-book arm China Literature, which became the city’s most profitable initial public offering in nearly a decade.

In November, Tencent became the first Chinese technology company to top US$500 billion in market value. A US$1,764 investment in the company’s 2004 public offering would be worth US$1 million, after taking a 2014 stock split into consideration. That represents a 500-fold rise in the stock value of China’s biggest social network operator.
As this year winds down, tech stocks have posted remarkable gains. The S&P North American technology index has jumped 38 per cent against a 20 per cent increase for the S&P 500 index. The Hang Seng Composite Information Technology Index has surged 88 per cent against the broader benchmark’s 33 per cent rise.
Market experts expect to see continued rosy prospects in 2018.

Weibo Corp
YTD gain: 166 per cent
The Nasdaq-traded Chinese social media operator, which runs the Twitter-like microblogging service Sina Weibo, had eclipsed its US rival in terms of market capitalisation in February this year.
Headquartered in Beijing, Weibo added 79 million monthly active users year on year in the third quarter to swell its total user base to 376 million – about 46 million more subscribers than Twitter.
Weibo also made a net profit of US$101.1 million in the quarter ended September 30, while Twitter reported a net loss of US$21 million in the same period.

BeiGene
YTD gain: 219.4 per cent
The Beijing-based biopharmaceutical company hit a home run this year amid a global boom in the immunotherapy market. It has developed four clinical stage therapies designed to boost patients’ immune system in cancer treatment.

It recently completed building a manufacturing plant in Suzhou Industrial Park, located in the eastern-central coastal province of Jiangsu. With a market capitalisation of about US$4 billion, BeiGene landed a US$1.39 billion deal in July with American biotechnology giant Celgene that marked the biggest overseas licensing of drugs developed in China to date. That represented the second major endorsement for BeiGene after it signed a global partnership with Merck Serono, the biopharmaceutical division of Merck, in 2013.

Xunlei
YTD gain: 277.2 per cent
The Shenzhen-based provider of internet services, including network download, video playback, digital content and online games, is among a growing number of small publicly traded companies to benefit from the rapid increase in value of cryptocurrencies.
Xunlei was recently on a tear – its share price rising about six-fold to become one of the best-performing stocks on the Nasdaq – after a subsidiary introduced a cryptocurrency project called “Wanke coin mining” in October.
The company, however, later distanced itself from that project amid the Chinese government’s clampdown on initial coin offerings. Worries over the project led to an internal scuffle with an associate company, Shenzhen Xunlei Big Data Information Services.
Wang Chuan, a co-founder of Chinese smartphone supplier Xiaomi, recently took over as chairman of Xunlei, putting an end to that dispute.

Leave a Reply

Your email address will not be published. Required fields are marked *